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infection. None of the patients in the study had a fever. The
diagnosis of infection was never based on biochemical measure-
ments of C-reactive protein alone.
Commercially available blood collection tubes and heparin used
for anticoagulation may be contaminated with endotoxin (5,6).
Therefore, in our study, the use of standard tubes for the
assessment of endotoxin concentrations in plasma was validated: 1)
Aliquots from the blood sampling tubes were filled with
endotoxin-free cell culture medium and tested for endotoxin after
comparable sample handling. No endotoxin was detected by the
commercial test kit used. 2) To further exclude contamination of
samples by endotoxin, a sensitive bioassay was used to measure in
vitro endothelial cell activation for neutrophil transmigration (7).
Aliquots from blood sampling tubes filled with endotoxin-free cell
culture medium with and without 10 mg/ml of polymyxin B had no
effect on endothelial cell activation for leukocyte transmigration,
thus confirming the lack of endotoxin contamination.
Rauchhaus et al. suggest an alternative hypothesis to explain
endotoxemia in terms of bacterial translocation across the intesti-
nal wall due to atherosclerotic processes in the mesenteric vascu-
lature. However, because the observed association between endo-
toxemia at baseline and carotid atherosclerosis at follow-up was
particularly pronounced in patients who had no coronary artery
disease and in whom there was no ultrasound evidence of carotid
and femoral artery atherosclerosis at baseline, it is unlikely that
intestinal ischemia with bacterial translocation was present in these
patients when endotoxin samples were obtained at baseline.
Furthermore, recent data show that elevated levels of antibodies to
lipopolysaccharide from Escherichia coli, probably reflecting suc-
cessful immune responses to intestinal translocation of bacteria, are
inversely related to carotid artery atherosclerosis and are not
associated with endotoxemia (manuscript submitted). These data
indirectly support a role of infections as a source of atherogenic
endotoxemia.
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Coronary Heart Disease
and Chlamydia pneumoniae
DNA in Blood Mononuclear Cells
The report by Wong et al. (1), on the detection of Chlamydia
pneumoniae (Cpn) DNA in the peripheral blood mononuclear cells
(PBMCs) of a small proportion (,10%) of patients with coronary
artery disease (CAD), raises several interesting issues. There is a
strong desire to have an easily determined marker of Cpn in the
arterial wall, because obtaining atheromatous tissue is likely to be
a rare event and serologic assessments, as pointed out by Wong et
al. and Kaski and Camm in the accompanying editorial (2), are of
no help. The question is whether the weak association between
Cpn DNA in PBMCs and CAD in men, said to be a predictor of
CAD, is meaningful. The same association was not seen for
women. Reasons for the failure to show the same association in
women are suggested (hormones?), but could it be that the lack of
association for women is the most plausible result? Surely those
without CAD in the age group studied are not devoid of
artheromatous changes in other major vessels; and Cpn DNA has
been detected in a large proportion of all major vessels examined
(3). Thus, if there is a relation between atheromatous lesions and
PBMCs carrying Cpn DNA, the latter finding might be expected
irrespective of the existence of CAD. Thought should be given to
the possibility that the positive association in men, despite statis-
tical significance, is spurious, and that the negative association in
women is not so bewildering. Curious, however, is the finding of
Cpn DNA in the PBMCs of ,10% of patients. Wong et al. (1)
regard the large proportion (.50%) of patients, including blood
donors, with such cells reported by Bowman et al. (4) in Sweden
to be remarkable; the Southampton workers refer to possible
geographic differences to explain these different proportions. We
are inclined to think that this is not plausible in view of some of
our observations in ongoing studies. Thus, in examining PBMCs
from subjects in the United Kingdom with peripheral vascular
disease, we have found 47% of the samples to be Cpn-positive by
polymerase chain reaction. In addition, donors ($15 years old) of
hearts for transplantation whose vessels (principally ascending
aorta and pulmonary artery) were Cpn-positive were less likely to
have spleen cells, presumably containing PBMCs, that were
Cpn-positive than were donors whose vessels were Cpn-negative.
Overall, 37% of the spleen specimens were positive. Therefore, we
think that the relation between Cpn DNA in circulating mono-
cytes and CAD remains enigmatic. Doubtless, the true situation
will become clear eventually. In the meanwhile, to suggest that
Cpn DNA in PBMCs is a predictor of CAD in men, but not in
women—that is, in ,10% of them—and that they stand out as
having an “active” infection and might benefit from antibiotic
therapy, seems misplaced. Fortunately, the antibiotic trials cur-
rently in progress are being undertaken with complete disregard for
the PBMC Cpn DNA status of the patients.
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REPLY
We thank Drs. Taylor-Robinson and Thomas for their interest in
our study, which found circulating Chlamydia pneumoniae (C.
pneumoniae) DNA to be associated with coronary artery disease
(CAD) in men but not women (1). The association in men was
moderate, with an odds ratio of 3.2 (95% confidence interval 1.1 to
8.9), and this was stronger than that reported in most serologic
studies (2). We discussed possible reasons for the lack of an
association in women, but because the number of male subjects was
over twice that of females, the statistical power to detect a
difference was strongest for men. In our study, patients and control
subjects were defined according to the presence of CAD by
angiographic criteria, an approach taken by other studies of C.
pneumoniae and CAD (2), and, indeed, by studies that have
investigated other coronary risk factors. We can justifiably claim
that we have found an association between C. pneumoniae DNA
and clinically significant atherosclerosis.
Our study and that of Boman et al. (3) are still the only
published reports on circulating C. pneumoniae DNA and CAD,
and we pointed out the differences in the reported prevalence of C.
pneumoniae DNA. In our view, the finding that circulating C.
pneumoniae DNA was found in 46% of a healthy, blood-donating
population (3) is remarkable and an extraordinarily high level for
any bacterium. However, although our study was far larger than
Boman’s, further work is required to clarify the situation, but we
cannot comment on the unpublished data of the correspondents or
their observations.
It would be generally accepted that evidence of current C.
pneumoniae infection should be found before prescribing antibiot-
ics to patients with CAD. At present, the presence of circulating
C. pneumoniae DNA is the most accurate method of diagnosing
current infection and is therefore a means of identifying suitable
patients for intervention trials. This was also a view held by the
correspondents (4), and we are therefore surprised by their state-
ment that “fortunately,” current antibiotic trials are being under-
taken with complete disregard for the PBMC C. pneumoniae
status. Fortunately, investigators running such trials do realize the
potential importance of such a test (5).
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The Electric Cardiographic
Abnormalities Are Not Hidden!
The report by Matetzky et al. (1) stimulates the following
thoughts. There are two ways to interpret electrocardiograms
(ECGs). One is to memorize patterns and the other is to use basic
principles of electrocardiography, including the use of vector
concepts, as described by Grant (2–6).
The tracing in Figure 1A of the report by Matetzky et al. reveals
a left atrial abnormality; a mean spatial QRS vector that is directed
at about 120° in the frontal plane (it changes direction during
inspiration and expiration) and about 45° posteriorly; a mean
spatial ST segment vector that is directed at 1115° in the frontal
plane and at least 90° posteriorly, indicating epicardial injury of the
posterior wall of the left ventricle; a mean spatial T-wave vector
that is directed at 190° in the frontal plane and 80° to 90°
anteriorly, indicating posterior myocardial ischemia; and a large U
wave in lead I.
The point is, the ST segment vector points toward an area of
posterior epicardial injury. Furthermore, one can suspect that the
ST segment vector is directed toward an obstruction in the
circumflex coronary artery or its branches. It should be no surprise
that the ST segment is elevated in leads V7–9, because the
transitional pathway was just beyond electrode position V6. The ST
segment abnormality is not hidden.
The follow-up discharge tracing in Figure 1B is also interesting.
The left atrial abnormality has disappeared; an S1, S2 and S3
conduction defect has developed; and the first half of the QRS
complex is directed at about 140° in the frontal plane and
markedly anterior, producing large abnormal R waves in leads V1
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